Cancer diagnostic firm Caris Life Sciences on Monday raised the proposed price range for its New York initial public offering, targeting a valuation of up to $5.67 billion and indicating a strong demand for fresh stock flotations. The Irving, Texas-based company is marketing the IPO of nearly 23.5 million shares between $19 and $20 apiece, compared with its earlier range of $16 to $18 per share. The IPO will raise $470.6 million at the higher end of the revised range.
Read the full article: Sixth Street-Backed Caris Lifts IPO Price Range, Eyes $5.7B Valuation //
Source: https://www.reuters.com/business/healthcare-pharmaceuticals/sixth-street-backed-caris-lifts-ipo-price-range-eyes-57-billion-valuation-2025-06-16/